273 related articles for article (PubMed ID: 33118847)
1. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
2. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
[TBL] [Abstract][Full Text] [Related]
4. Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study.
Chen H; Qi X; Li Y; Wu Q; Shi Q; Wang L; Li J; Zhao L; Zhang L; Zhou X; Fei Y; Liu J; Su J; Wu D; Yang Y; Jiang H; Zeng X; Zhang F; Zhao Y
Mod Rheumatol; 2021 Mar; 31(2):394-398. PubMed ID: 32613869
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren's Syndrome.
Zeng L; He Q; Yang K; Hao W; Yu G; Chen H
Front Immunol; 2022; 13():924730. PubMed ID: 35967307
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
Pu J; Wang X; Riaz F; Zhang T; Gao R; Pan S; Wu Z; Liang Y; Zhuang S; Tang J
Front Pharmacol; 2021; 12():621208. PubMed ID: 33815105
[No Abstract] [Full Text] [Related]
8. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis.
Hu G; Yu YF; Yin S; Yang XY; Xu Q; You H
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7544-7556. PubMed ID: 37667931
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
16. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
[TBL] [Abstract][Full Text] [Related]
18. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
[TBL] [Abstract][Full Text] [Related]
20. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.
Seror R; Ravaud P; Mariette X; Bootsma H; Theander E; Hansen A; Ramos-Casals M; Dörner T; Bombardieri S; Hachulla E; Brun JG; Kruize AA; Praprotnik S; Tomsic M; Gottenberg JE; Devauchelle V; Devita S; Vollenweider C; Mandl T; Tzioufas A; Carsons S; Saraux A; Sutcliffe N; Vitali C; Bowman SJ;
Ann Rheum Dis; 2011 Jun; 70(6):968-72. PubMed ID: 21345815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
